News

High pyridostigmine doses cause overactive bladder issues in people with myasthenia gravis (MG), according to a recent study. Because of this, doctors should take patients’ bladder-related discomfort into account when deciding treatment regimens, and consider prescribing lower pyridostigmine doses or alternative therapies. The study, “Overactive…

Soliris (eculizumab) was found in a real-world setting to safely and effectively treat adults with generalized myasthenia gravis (gMG) who had stopped responding to other treatments, according to a post-marketing surveillance study in Japan. The study “Safety and effectiveness of eculizumab in Japanese patients with…

Myasthenia gravis (MG) can mimic the symptoms of a stroke and should not be ruled out even in younger patients, a recent medical case report suggests. The report, “Myasthenia gravis masquerading as acute stroke: a case report,” was published in the PanAfrican Medical Journal. MG…

When used over long periods of time, Soliris (eculizumab) does not increase the risk of infections in people with generalized myasthenia gravis (gMG), according to a new analysis of clinical trial data. Findings from this post hoc analysis were presented this week at the 2021 MDA Virtual Clinical…

Myasthenia gravis (MG) crisis, the disease’s most severe state, is associated with pronounced pro-inflammatory cellular and molecular changes, a recent study shows. Notably, several pro-inflammatory immune cells and molecules were found to be associated with symptom severity, adding to previous data showing a link between certain pro-inflammatory cells…

Ra Pharmaceuticals is enrolling adults with generalized myasthenia gravis (gMG) in RAISE, its global and pivotal Phase 3 trial evaluating the safety and efficacy of zilucoplan, the Muscular Dystrophy Association (MDA) has announced. The company started preparing to launch the RAISE (NCT04115293) study in early…